This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investigation on Behalf of OvaScience, Inc. Investors Announced by Kirby McInerney LLP

The law firm of Kirby McInerney LLP announced today that a class action lawsuit has been commenced in the United States District Court for the District of Connecticut on behalf of investors who acquired OvaScience, Inc. (“OvaScience” or the “Company”) (NASDAQ-GM:OVAS) securities from February 25, 2013 through September 10, 2013. By law, investors have until August 5, 2014 to file a motion to be appointed as lead plaintiff in the investor lawsuit.

The lawsuit alleges that the Company violated the Securities Exchange Act of 1934 by failing to disclose during the Class Period that the Company’s core product, AUGMENT, a fertility enhancing process, would not be allowed to be tested using the FDA’s less stringent HCT/P oversight procedures, as previously announced. Instead, the product would likely have to be fully evaluated through the traditional FDA approval process, which is vastly more time consuming and expensive. When defendants finally admitted that the product’s HCT/P status was called into question by the FDA, and investors realized that this would deeply disrupt both the budget and timeline for the commercialization of the product, the Company’s stock declined over 23%.

If you acquired OvaScience securities during this period and you are interested in learning more about this matter and any rights you might have with respect to these claims, contact Wilona Karnadi or Jess Kelley at securitiescases@kmllp.com, by telephone at (212) 371-6600, or by filling out this form. Please bear in mind that some of these rights may be time-sensitive.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, whistleblower, antitrust and consumer litigation. The firm has specialized in complex litigation, including securities class actions, for several decades. Kirby McInerney LLP has repeatedly demonstrated its expertise in this field, and has been recognized by various courts that have appointed the firm to major positions in consolidated and multi-district litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars, and the firm’s achievements and quality of service have been chronicled in numerous published decisions. Additional information about the firm or the claims against OvaScience can be found at Kirby McInerney LLP’s website:  http://www.kmllp.com.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,094.22 +56.25 0.31%
S&P 500 2,112.43 +3.51 0.17%
NASDAQ 5,064.9490 +4.7030 0.09%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs